[HTML][HTML] Liposome-based diagnostic and therapeutic applications for pancreatic cancer
Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …
Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications
L Cao, J Wu, X Qu, J Sheng, M Cui, S Liu… - Journal of Experimental …, 2020 - Springer
Pancreatic cancer is one of the most malignant tumors worldwide, and pancreatic ductal
adenocarcinoma is the most common type. In pancreatic cancer, glycolysis is the primary …
adenocarcinoma is the most common type. In pancreatic cancer, glycolysis is the primary …
[HTML][HTML] Vive la radiorésistance!: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and …
While many efforts have been made to pave the way toward human space colonization, little
consideration has been given to the methods of protecting spacefarers against harsh cosmic …
consideration has been given to the methods of protecting spacefarers against harsh cosmic …
Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer
EK Silli, M Li, Y Shao, Y Zhang, G Hou, J Du… - European Journal of …, 2023 - Elsevier
Pancreatic cancer (PC) is an incurable disease with a high death rate in the world
nowadays. Gemcitabine (GEM) and Paclitaxel (PTX) are considered as references of …
nowadays. Gemcitabine (GEM) and Paclitaxel (PTX) are considered as references of …
[HTML][HTML] Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway
C Yu, S Chen, Y Guo, C Sun - Theranostics, 2018 - ncbi.nlm.nih.gov
Background: Drug resistance is well known as a major obstacle for cancer recurrence and
treatment failure, leading to poor survival in pancreatic cancer, which is a highly aggressive …
treatment failure, leading to poor survival in pancreatic cancer, which is a highly aggressive …
Combined exosomal GPC1, CD82, and serum CA19-9 as multiplex targets: a specific, sensitive, and reproducible detection panel for the diagnosis of pancreatic …
D **ao, Z Dong, L Zhen, G **a, X Huang, T Wang… - Molecular cancer …, 2020 - AACR
Pancreatic cancer is a highly lethal malignancy with poor prognosis due to the lack of early
symptoms and resultant late diagnosis. Thus, it is extremely urgent to establish a simple and …
symptoms and resultant late diagnosis. Thus, it is extremely urgent to establish a simple and …
Pancreatic cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management
Simple Summary Pancreatic ductal adenocarcinoma is a devastating disease that is very
hard to treat. Here, we advance and evaluate the notion that the best possible management …
hard to treat. Here, we advance and evaluate the notion that the best possible management …
[HTML][HTML] Metabolomic biomarkers of pancreatic cancer: a meta-analysis study
Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …
no blood test for early detection and diagnosis of this disease. Several research groups …
Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal …
T Igarashi, M Fukasawa, T Watanabe… - Annals of …, 2024 - Wiley Online Library
Introduction The prognosis of pancreatic ductal adenocarcinoma (PDAC) in patients with
positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of …
positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of …
Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives
L Pekarek, O Fraile-Martinez… - Oncology …, 2021 - spandidos-publications.com
Pancreatic cancer has a dire prognosis and will represent the second leading cause of
cancer death in the next 10 years. The multifactorial approach represents one of the main …
cancer death in the next 10 years. The multifactorial approach represents one of the main …